MicroMIR

MIR Journal provides a platform for high-quality research in virology, bacteriology, mycology, antimicrobial resistance, infectious diseases, molecular microbiology, biotechnology, vaccine research, and antimicrobial and antiviral drug development. It serves researchers and professionals working in academia, healthcare, biotechnology, and the pharmaceutical and biopharmaceutical industries.

MIR Journal publishes original research articles, reviews and mini-reviews, short communications, case reports, hypotheses, commentaries, and editorials.

All submitted manuscripts undergo an initial scientific and editorial assessment. Manuscripts selected for further consideration are evaluated in accordance with the journal’s peer-review policy. Research articles are subject to independent peer review. The journal is committed to scientific rigor, research integrity, editorial independence, and responsible open-access publishing.

Open Access and International Visibility

MIR Journal is a fully open-access journal that provides immediate and unrestricted online access to its published content.

Articles are published under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license permits the use, distribution, adaptation, and reproduction of published material in any medium or format, provided that appropriate credit is given to the original authors and source, a link to the license is included, and any changes are clearly indicated.

MIR Journal does not charge authors article processing charges or publication fees.

The journal is hosted and distributed through the ScienceOpen publishing platform. MIR Journal is indexed, abstracted, or discoverable through major international scholarly services, including DOAJ, Chemical Abstracts Service (CAS), EBSCO, Google Scholar, Crossref, OpenAlex, OpenAIRE, CORE, BASE, Scilit, J-Gate, Ulrichsweb, ScienceGate, and eLIBRARY.RU. The journal is also listed in the NLM Catalog.

Long-term digital preservation of MIR Journal content is provided through the Zenodo repository and the CLOCKSS Archive.

According to readership statistics, MIR Journal articles have reached readers in more than 160 countries, supporting the journal’s mission to make microbiological research accessible to a broad international scientific community.

Aim and Scope

MIR Journal welcomes fundamental, translational, and applied research addressing microorganisms, infectious diseases, host–pathogen interactions, and technologies for their prevention, diagnosis, and treatment.

Major areas of interest include:

• Virology and viral pathogenesis, including emerging and re-emerging viruses;
• Bacteriology and bacterial pathogenesis;
• Medical and applied mycology;
• Antimicrobial resistance, including its mechanisms, epidemiology, surveillance, and One Health dimensions;
• Vaccine research and development, including conventional, recombinant, viral-vector, mucosal, and universal vaccine platforms;
• Mechanisms of viral attenuation and vaccine-strain adaptation;
• Vaccine manufacturing and cell-based production technologies;
• Antiviral and antimicrobial drug discovery, including mechanisms of action, resistance, and novel therapeutic targets;
• Clinical microbiology, molecular diagnostics, and infectious-disease epidemiology;
• Microbial genomics, molecular biology, and host–pathogen interactions;
• Microbiomes and their relevance to human and animal health;
• Plasmid and viral vectors and their applications in biotechnology and medicine;
• Synthetic and systems microbiology;
• Environmental microbiology and microbial ecology, particularly where relevant to infectious diseases and antimicrobial resistance;
• The molecular structure, synthesis, and function of biomolecules essential to microbial and viral life cycles; and
• Emerging technologies and computational approaches in microbiology, including bioinformatics and artificial intelligence.

Particular consideration is given to studies that combine scientific novelty with biomedical, clinical, epidemiological, or biotechnological significance.